Gadodiamide
Identification
- Name
- Gadodiamide
- Accession Number
- DB00225
- Description
Gadodiamide is a paramagnetic gadolinium-based contrast agent (GBCA) that is used in MR imaging procedures to assist in the visualization of blood vessels. It is intravenously injected and is commonly marketed under the trade name Omniscan.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Gadodiamide (DB00225)
- Weight
- Average: 573.66
Monoisotopic: 574.10225 - Chemical Formula
- C16H26GdN5O8
- Synonyms
- Gadodiamida
- Gadodiamide
- Gadodiamide anhydrous
- External IDs
- S-041
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
For intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues.
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
- Not Available
- Mechanism of action
Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, gadodiamide shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, gadodiamide primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadodiamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadodiamide in lesions such as neoplasms, abscesses, and subacute infarcts.
- Absorption
- Not Available
- Volume of distribution
- 200 ± 61 mL/kg
- Protein binding
- Not Available
- Metabolism
There is no detectable biotransformation or decomposition of gadodiamide.
- Route of elimination
Gadodiamide is eliminated primarily in the urine.
- Half-life
Two-compartment model with mean distribution and elimination half-lives (reported as mean ± SD) of 3.7 ± 2.7 minutes and 77.8 ± 16 minutes, respectively.
- Clearance
- Renal cl=1.7 mL/min/kg
- Plasma cl=1.8 mL/min/kg
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Gadodiamide may decrease the excretion rate of Abacavir which could result in a higher serum level. Aceclofenac Aceclofenac may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Acetaminophen Gadodiamide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Gadodiamide which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Aclidinium Gadodiamide may decrease the excretion rate of Aclidinium which could result in a higher serum level. Acrivastine Gadodiamide may decrease the excretion rate of Acrivastine which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Gadodiamide which could result in a higher serum level. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Gadodiamide which could result in a higher serum level. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- No interactions found.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Gadodiamide hydrate 0RPE15QPL0 122795-43-1 WYKPQCVMUQQKCL-UHFFFAOYSA-K - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Omniscan Injection 287 mg/1mL Intravenous GE Healthcare Inc. 2002-04-19 Not applicable US 
Omniscan Injection 287 mg/1mL Intravenous GE Healthcare Inc. 2006-09-21 Not applicable US Omniscan Solution 287 mg Intravenous Ge Healthcare 1997-03-25 Not applicable Canada 
Omniscan Liq IV 287mg/ml Liquid Intravenous Sanofi 1994-12-31 1997-07-30 Canada
Categories
- ATC Codes
- V08CA03 — Gadodiamide
- Drug Categories
- Acetates
- Acids, Acyclic
- Amines
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Diagnostic Uses of Chemicals
- Drugs that are Mainly Renally Excreted
- Fatty Acids
- Fatty Acids, Volatile
- Injections, Intravenous
- Lipids
- Magnetic Resonance Contrast Activity
- Magnetic Resonance Imaging Contrast Media
- Miscellaneous Therapeutic Agents
- Organometallic Compounds
- Other Diagnostics
- Paramagnetic Contrast Agent
- Paramagnetic Contrast Media
- Polyamines
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- Alpha amino acids / Tricarboxylic acids and derivatives / Trialkylamines / Secondary carboxylic acid amides / Carboxylic acid salts / Amino acids / Carboxylic acids / Organopnictogen compounds / Organic zwitterions / Organic salts show 3 more
- Substituents
- Aliphatic acyclic compound / Alpha-amino acid / Alpha-amino acid amide / Amine / Amino acid / Carbonyl group / Carboxamide group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative show 12 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- gadolinium coordination entity (CHEBI:37333)
Chemical Identifiers
- UNII
- 84F6U3J2R6
- CAS number
- 131410-48-5
- InChI Key
- HZHFFEYYPYZMNU-UHFFFAOYSA-K
- InChI
- InChI=1S/C16H29N5O8.Gd/c1-17-12(22)7-20(10-15(26)27)5-3-19(9-14(24)25)4-6-21(11-16(28)29)8-13(23)18-2;/h3-11H2,1-2H3,(H,17,22)(H,18,23)(H,24,25)(H,26,27)(H,28,29);/q;+3/p-3
- IUPAC Name
- gadolinium(3+) 2-[bis({2-[(carboxylatomethyl)[(methylcarbamoyl)methyl]amino]ethyl})amino]acetate
- SMILES
- [Gd+3].CNC(=O)CN(CCN(CCN(CC([O-])=O)CC(=O)NC)CC([O-])=O)CC([O-])=O
References
- General References
- Not Available
- External Links
- PubChem Compound
- 24847884
- PubChem Substance
- 46504789
- ChemSpider
- 135661
- 41144
- ChEBI
- 37333
- PharmGKB
- PA164784027
- RxList
- RxList Drug Page
- Wikipedia
- Gadodiamide
- AHFS Codes
- 92:00.00 — Miscellaneous Therapeutic Agents
- 36:89.00* — Other Diagnostics
- MSDS
- Download (56.3 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Chronic Kidney Disease (CKD) / Impaired kidney function 1 4 Not Yet Recruiting Other Cognitive Function / Contrast Media / Motor Function 1 3 Completed Diagnostic Anatomic renal artery stenosis 1 3 Completed Diagnostic Aorto-Iliac Stenosis / Arterial Occlusive Diseases 1
Pharmacoeconomics
- Manufacturers
- Ge healthcare
- Packagers
- Amersham Health Inc.
- GE Healthcare Inc.
- Dosage Forms
Form Route Strength Injection, solution Intravenous 287 mg/ml Injection Intravenous 287 mg/ml Injection Intravenous 287 mg/1mL Solution Intravenous 287 mg/1ml Injection, solution Intravenous 0.5 mmol/ml Liquid Intravenous Solution Intravenous 287 mg Solution Intravenous 287 mg/ml - Prices
Unit description Cost Unit Omniscan prefill plus syringe 7.02USD ml Omniscan 287 mg/ml vial 6.98USD ml Omniscan 287 mg/ml bottle 6.49USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5560903 No 1996-10-01 2013-10-01 US US5362475 No 1994-11-08 2011-11-08 US CA1335819 No 1995-06-06 2012-06-06 Canada
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 5.21 mg/mL ALOGPS logP 0.02 ALOGPS logP -8.7 ChemAxon logS -2.1 ALOGPS pKa (Strongest Acidic) 1.02 ChemAxon pKa (Strongest Basic) 8.34 ChemAxon Physiological Charge -2 ChemAxon Hydrogen Acceptor Count 11 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 188.31 Å2 ChemAxon Rotatable Bond Count 16 ChemAxon Refractivity 132.4 m3·mol-1 ChemAxon Polarizability 40.47 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.9808 Blood Brain Barrier + 0.62 Caco-2 permeable - 0.5605 P-glycoprotein substrate Substrate 0.7041 P-glycoprotein inhibitor I Non-inhibitor 0.9016 P-glycoprotein inhibitor II Non-inhibitor 0.9571 Renal organic cation transporter Non-inhibitor 0.9031 CYP450 2C9 substrate Non-substrate 0.8265 CYP450 2D6 substrate Non-substrate 0.8189 CYP450 3A4 substrate Non-substrate 0.5872 CYP450 1A2 substrate Non-inhibitor 0.9416 CYP450 2C9 inhibitor Non-inhibitor 0.9189 CYP450 2D6 inhibitor Non-inhibitor 0.9566 CYP450 2C19 inhibitor Non-inhibitor 0.8972 CYP450 3A4 inhibitor Non-inhibitor 0.9864 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9927 Ames test Non AMES toxic 0.8343 Carcinogenicity Non-carcinogens 0.8563 Biodegradation Not ready biodegradable 0.7604 Rat acute toxicity 1.9159 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9582 hERG inhibition (predictor II) Non-inhibitor 0.9424
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Drug created on June 13, 2005 13:24 / Updated on March 04, 2021 11:39